KERX one of my favorites

Anyone looking for guaranteed returns should take a look at KERX. I am long in KERX since $4. It has a PDUFA date of June 7 2014 for its drug Zerenex. Note that this drug has already been approved in the European and Asian markets and is currently been marketed in Asia by Japan Tobacco. To cut long story short I see the price target of $25 by June and can possibly run upto $35 based on its sales projections. Recent pull back (coz of covering of shorts) presents a great opportunity to go long on KERX. Even if you get in at this level there is a potential to make 115% returns by June.

About Keryx Biopharmaceuticals, Inc.:

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate coordination complex), an oral, ferric iron-based compound. Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease on dialysis, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx's New Drug Application (NDA), submitted to the FDA in 2013, is currently under review and has an assigned Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014. The Marketing Authorization Application (MAA) filing with the European Medicines Agency (EMA) is pending. Zerenex has also completed a Phase 2 study in the U.S. for the management of elevated serum phosphorus levels and iron deficiency anemia in patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd., received marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease on January 17, 2014. Keryx is headquartered in New York City.